At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 130 enrolled
Drug / intervention
entinostat +2 moredrug
Likely dose
entinostat 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 2, Randomized, Double-Blind, Multicenter Study of Exemestane With and Without SNDX-275 in Postmenopausal Women With Locally Recurrent or Metastatic Estrogen Receptor-Positive Breast Cancer, Progressing on Treatment With a Non-Steroidal Aromatase Inhibitor
In Brief
A Phase 2 clinical trial evaluating entinostat, exemestane, and 1 other intervention for Breast Cancer and 3 related conditions. Completed, enrolled 130 participants across 38 sites in 5 countries.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of entinostat in combination with exemestane in the treatment of advanced breast cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Estrogen Receptor-Positive Breast Cancer, Breast Cancer, Estrogen Receptor-Positive, ER+ Breast Cancer
CountriesCanada, Czechia, Hungary, Russia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMay 2008
Enrollment StartJun 2008
Primary CompletionJan 2011
Study CompletionNov 2012
TodayJul 2026
First PostedMay 13, 2008
Enrollment StartJun 13, 2008
Primary CompletionJan 29, 2011
Study CompletionNov 26, 2012
TodayJul 2, 2026
Enrollment to primary: 2.6 yearsPosted 18.1 years ago
Interventions
entinostatdrug
Entinostat 5 mg tablet orally once per week
exemestanedrug
Exemestane 25 mg tablet orally once daily
Placebodrug
Placebo-matching entinostat tablet orally once per week